Human IFN-gamma Antibody

Name: Human IFN-gamma Antibody
Brand: R&D Systems
SKU: AB-285-NA
Price: 489 USD
Availability: InStock

R&D Systems | Catalog # AB-285-NA

Submit a review

Citations (6)

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Western Blot, Neutralization

Cited:

Neutralization, Functional Assay

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

View all IFN-gamma Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human IFN-gamma
Met1-Gln144
Accession # P01579

Specificity

Detects human IFN-gamma in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 50% cross-reactivity with recombinant rhesus monkey IFN‑ gamma is observed, and less than 5% cross-reactivity with recombinant mouse IFN‑ gamma, recombinant canine IFN‑ gamma, recombinant porcine IFN‑ gamma, recombinant bovine IFN‑ gamma, recombinant rat IFN‑ gamma, recombinant feline IFN‑ gamma, and recombinant equine IFN‑ gamma is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IFN-gamma Antibody

Human IFN‑ gamma Antibody Neutralization.

Measured by its ability to neutralize IFN‑gamma inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. The Neutralization Dose (ND₅₀) is typically <20 µg/mL.

Detection of IFN-gamma by Flow Cytometry

Flow cytometric analysis of B cells activated during the early priming or late differentiation phase with IFN gamma, R848 or IL-21.HD BN cells were activated as described in Figure 5a. Representative flow cytometry plots from cultures containing IFN gamma (a–c), R848 (d–f) or IL-21 (g–i) are provided and indicate the frequencies of T-bethiIRF4int B cells on day 3 (a, d, g), CD38hiCD27+ ASCs on day 6 (b, e, h) and CTV dilution on day 6 (c, f, i). Quantitation across multiple experiments (n ≥ 3 with independent donors) shown in Figure 5. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31090539), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of IFN-gamma by Flow Cytometry

Applications for Human IFN-gamma Antibody

Application

Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Human IFN-gamma (Catalog # 285-IF)

Neutralization

Measured by its ability to neutralize IFN‑ gamma inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line [Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129]. The Neutralization Dose (ND₅₀) is typically <20.0 µg/mL in the presence of 5 ng/mL Recombinant Human IFN‑ gamma.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: IFN-gamma

Interferon-gamma (IFN-gamma, IFNG), also known as type II or Immune Interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine. Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa molecular weight variably glycosylated subunits. Glycosylation of IFN-gamma at sites Asn25 and Asn97 is critical for protease resistance. It shares 90% amino acid (aa) sequence identity with rhesus IFN-gamma, 59-64% with bovine, canine, equine, feline, and porcine IFN‑ gamma, and 37-43% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction. IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key function in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up‑regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects. In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation. The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis.